Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050978 | 0.92 | SMN1; SMN2 (0.46) | OPRD1OPRK1JAK2JAK1GRIN2B | |
| SCHEMBL28938318 | 0.92 | SMN1; SMN2 (0.46) | OPRD1OPRK1JAK2JAK1GRIN2B | |
| SCHEMBL14654247 | 0.91 | JAK2 (0.47) | OPRD1OPRK1JAK2JAK1GRIN2B | |
| SCHEMBL14647469 | 0.91 | JAK2 (0.47) | OPRD1OPRK1JAK2JAK1GRIN2B | |
| SCHEMBL593236 | 0.90 | SMN1; SMN2 (0.50) | OPRD1OPRK1JAK2JAK1GRIN2B | |
| SCHEMBL2327296 | 0.88 | JAK2 (0.44) | OPRD1OPRK1JAK2JAK1GRIN2B | |
| SCHEMBL2323403 | 0.85 | GRIN2B (0.43) | OPRD1OPRK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL2323399 | 0.85 | GRIN2B (0.43) | OPRD1OPRK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL15878148 | 0.83 | F2 (0.38) | OPRD1OPRK1GRIN2BSMN1; SMN2NPC1 | |
| SCHEMBL15877464 | 0.83 | F2 (0.38) | OPRD1OPRK1GRIN2BSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715626-B | Heterocyclic compounds as FGFR inhibitors | 广州诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2020-08-25 | — | — | US | disclosed |
| EP-3498706-A1 | HETEROCYCLIC COMPOUND AS FGFR INHIBITOR | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| EP-2534151-B1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2018-11-14 | — | — | EP | disclosed |
| US-8658794-B2 | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof | MERCK SHARP & DOHME B.V. (NL) | 2014-02-25 | — | — | US | disclosed |
| EP-2534151-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MSD Oss B.V. (NL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2012-12-06 | — | — | US | disclosed |
| WO-2011095556-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | LCK, ZAP70, FYN | OPRD1 2856/4885OPRK1 1333/4885JAK2 155/4885 |
| US-20190177333-A1 | HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR | FGFR1, FGFR3, FGFR2 | OPRD1 3839/4885OPRK1 3566/4885JAK2 73/4885 |
| US-10752631-B2 | Heterocyclic compounds as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | OPRD1 3870/4885OPRK1 3589/4885JAK2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.